14K shares changed hands in the last trading session. Shares saw a steep decrease in trading volume of 89.93% under the normal average daily volume.
Short traders are more bullish of late if you consider the decrease in short interest. The stock saw a fall in short interest of -0.15% as of October 13, 2017 from the last reporting period. Short interest decreased from 427,396 to 426,739 over that timeframe. The short-interest ratio decreased to 8.0 and the percentage of shorted shares is inf% as of October 13.
The following firms have recently changed their position in GCVRZ. Gamco Investors, Inc. Et Al expanded its stake by buying 500 shares an increase of 0.8% in the quarter. Gamco Investors, Inc. Et Al now controls 63,100 shares valued at $23,000. The value of the position overall is down by 4.2%. As of quarter end Ameriprise Financial Inc had acquired 80 shares growing its holdings by 1.5%. The value of the total investment in Sanofi Cvr decreased from $2,000 to $2,000 a change of $0 since the last quarter.
Next Financial Group, Inc added to its holdings by buying 235 shares an increase of 235.0%. Next Financial Group, Inc currently owns 335 shares with a value of $0. The total value of its holdings decreased nan%. As of the end of the quarter Citadel Advisors LLC had bought a total of 35,670 shares growing its position 68.9%. The value of the investment in Sanofi Cvr went from $20,000 to $31,000 a change of 55.0% quarter to quarter.
The company is unchanged since yesterday’s close of .
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France..